Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pegasys (Hoffmann-La Roche).

D L Barnard1

  • 1Institute for Antiviral Research, Utah State University, Logan 84322-5600, USA. honery@cc.usu.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vitro and in vivo influenza virus-inhibitory effects of viramidine.

Antiviral research·2005
Same author

Antiviral research - 13th International Conference.

IDrugs : the investigational drugs journal·2005
Same author

Antiviral Research - 15th International Conference. Mega-HAART and tenofovir. 17-21 March 2002, Prague, Czech Republic.

IDrugs : the investigational drugs journal·2004
Same author

In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity.

Antimicrobial agents and chemotherapy·2004
Same author

Fulminant Crohn's colitis after allogeneic stem cell transplantation.

Gut·2003
Same author

Pulmonary complications following bone marrow transplantation.

The British journal of radiology·2003
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Pegasys, a PEGylated interferon alpha-2a, is being developed for chronic hepatitis C and B. Regulatory submissions and approvals are ongoing globally, with potential for combination therapy and expanded indications.

Area of Science:

  • Hepatology and Virology
  • Pharmacology and Drug Development
  • Biotechnology and Pharmaceutical Sciences

Background:

  • Chronic hepatitis C (HCV) and hepatitis B (HBV) infections represent significant global health challenges.
  • Interferon alpha-2a is a known antiviral agent, but its efficacy is limited by administration and side effect profiles.
  • PEGylation technology aims to improve the pharmacokinetic and pharmacodynamic properties of protein-based therapeutics.

Purpose of the Study:

  • To develop and seek regulatory approval for Pegasys (PEGylated interferon alpha-2a) as a novel treatment for chronic HCV and HBV infections.
  • To evaluate the safety and efficacy of Pegasys in diverse patient populations, including those with compensated liver disease.
  • To explore potential combination therapies and expanded indications for Pegasys, including various malignancies.

Related Experiment Videos

Main Methods:

  • Development of PEGylated interferon alpha-2a (Pegasys) by Hoffmann-La Roche.
  • Submission of Biologics License Application (BLA) to the US FDA and filings in the EU, Canada, and Brazil.
  • Conducting Phase II clinical trials in Japan and utilizing foreign Phase III data for regulatory submissions.
  • Collaboration with pharmaceutical partners for drug delivery systems (e.g., needle-free injectors) and combination therapies.

Main Results:

  • Initial approval obtained in Switzerland in August 2001.
  • Regulatory review processes ongoing in the US, with a complete response letter received in April 2001.
  • Anticipated US launch in the second half of 2001, with projected approvals for HCV in 2002 and HBV in 2004.
  • Licensing agreements established to settle patent disputes and facilitate cross-licensing of PEGylated interferon products.
  • Significant sales potential predicted by financial analysts, indicating strong market expectations.

Conclusions:

  • Pegasys represents a significant advancement in the treatment of chronic viral hepatitis.
  • The strategic development and regulatory pathway indicate a strong potential for market success.
  • Ongoing research and collaborations aim to maximize the therapeutic utility of Pegasys.